US6440435B1 - Use of N-acylamino acid compounds as texturing agents - Google Patents

Use of N-acylamino acid compounds as texturing agents Download PDF

Info

Publication number
US6440435B1
US6440435B1 US09/845,199 US84519901A US6440435B1 US 6440435 B1 US6440435 B1 US 6440435B1 US 84519901 A US84519901 A US 84519901A US 6440435 B1 US6440435 B1 US 6440435B1
Authority
US
United States
Prior art keywords
composition
formula
water
weight
sepicide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/845,199
Inventor
Nelly Michel
Christian Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority to US09/845,199 priority Critical patent/US6440435B1/en
Application granted granted Critical
Publication of US6440435B1 publication Critical patent/US6440435B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/12Face or body powders for grooming, adorning or absorbing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14Preparations for removing make-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/002Aftershave preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Definitions

  • the present invention relates to a novel use of N-acylamino acid derivatives.
  • These compounds for example those described in the international patent applications published under the numbers WO 92/20647, WO 92/21318, WO 94/26694, WO 94/27561 and WO 98/09611, are, in particular on account of their antimicrobial and antielastic activity, used as active agents in formulations for topical use.
  • Such cosmetic, dermopharmaceutical or pharmaceutical formulations intended to care for the skin or mucous membranes must be easy to take up with the fingers before they are applied; when they are applied on the skin or on mucous membranes, they must spread easily, penetrate quickly and melt in well while at the same time affording sensations of freshness and softness, without being perceived as greasy or oily, and, after they have been applied to the skin or mucous membranes, they must not give rise to any sheen on the skin, or any unpleasant odour, or appear sticky; however, the sensations of softness and freshness resulting from their application must remain.
  • N-acylamino acid derivatives can be used effectively as texturing agents for cosmetic, dermopharmaceutical or pharmaceutical formulations.
  • R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid
  • the fragment R—CO comprises from 12 to 22 carbon atoms and more particularly from 16 to 22 carbon atoms
  • R 1 represents the characterizing chain or cyclic radical of an amino acid
  • R 2 represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or the topically acceptable salts thereof, as texturing agents, it being understood that the amino acid characterized by R 1 is not lysine, hydroxylysine or
  • topically acceptable salt means any salt of the acid of formula (I) which is biologically acceptable for the skin and/or mucous membranes, i.e., any salt which can in particular adjust the pH of the composition to a value of between 3 and 8 and preferably approximately equal to 5, which is a pH in the region of the skin's pH.
  • alkali metal salts such as sodium, potassium or lithium salts
  • alkaline-earth metal salts such as calcium, magnesium or strontium salts
  • they can also be metal salts such as divalent zinc, copper or manganese salts or alternatively trivalent iron, lanthanum, cerium or aluminium salts.
  • the compound of formula (I) present in the composition which is the subject of the present invention can be in free acid form or in partially or totally salified form.
  • the expression “characterizing chain” used in the context of the present patent application denotes the main chain of the fatty acid or of the amino acid under consideration. Thus, for a fatty acid corresponding to the general formula R—COOH, the characterizing chain will be the chain represented by R.
  • the linear or branched, saturated or unsaturated radical R represents a radical comprising from 11 to 21 carbon atoms, chosen, for example, from undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, uneicosyl, docosyl, heptadecenyl, eicosenyl, uneicosenyl and heptadecadienyl radicals.
  • a subject of the invention is, more particularly, the use as defined above, for which, in formula (I), the fragment R—CO represents in particular one of the following radicals: dodecanoyl (lauroyl), tetradecanoyl (myristyl), hexadecanoyl (palmitoyl), octadecanoyl (stearyl), eicosanoyl (arachidoyl), docosanoyl (behenoyl), octadecenoyl (oleyl), eicosenoyl (gadoloyl), docosenoyl (erucyl) or octadecadienoyl (linolenoyl).
  • dodecanoyl (lauroyl), tetradecanoyl (myristyl), hexadecanoyl (palmitoyl), octadecanoyl (ste
  • the chain or the cyclic radical characterizing the amino acid are chosen from those of glycine, alanine, serine, aspartic acid, glutamic acid, valine, threonine, proline, leucine, phenylalanine, isoleucine, histidine, tyrosine, tryptophan, asparagine, cysteine, cystine, methionine, hydroxyproline, ornithine and sarcosine.
  • a subject of the invention is, more particularly, the use as described above for which, in formula (I), the chain or the cyclic radical characterizing the amino acid are chosen from those of glycine, proline, glutamic acid and sarcosine.
  • At least one compound of formula (I) means that the invention can be carried out with one or more of these compounds.
  • the expression “or more of these compounds” means:
  • mixtures of fatty acids of natural origin which can be used advantageously for the preparation of the compounds of formula (I) are, in particular, those derived from coconut oil, palm kernel oil, palm oil, soybean oil, rapeseed oil, bovine tallow, spermaceti oil, herring oil or castor oil.
  • a mixture comprising at least one compound of formula (Ia) corresponding to formula (I), in which the cyclic radical characterizing the amino acid is that of praline, and at least one compound of formula (Ib) corresponding to formula (I) in which the characterizing chain of the amino acid is that of glutamic acid, and optionally at least one compound of formula (Ic) corresponding to formula (I) in which R 2 represents a methyl radical and R 1 represents the characterizing chain of sarcosine; as an example of such a use, mention may be made of the use of the mixture comprising N-palmitoylproline and N-palmitoylglutamic acid or the sodium or magnesium salts thereof or the use of the mixture comprising N-palmitoylproline, N-palmitoylglutamic acid and N-palmitoylsarcosine or the sodium or magnesium salts thereof.
  • its subject is the use, as described above, of a composition comprising N-cocoylglycine or one of the topically acceptable salts thereof.
  • a subject of the invention is also a composition (A) comprising;
  • R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid comprising from 12 to 22 carbon atoms
  • R represents the chain or the cyclic radical characterizing the amino acid, chosen from those of glycine, alanine, serine, aspartic acid, glutamic acid, valine, threonine, proline, leucine, phenylalanine, isoleucine, histidine, tyrosine, tryptophan, asparagine, cysteine, cystine, methionine, hydroxyproline, ornithine and sarcosine, R, represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or one of the topically acceptable salts thereof, and R 2 represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or one of the topically acceptable salts thereof, and
  • a subject of the invention is, more particularly, a composition (A) as defined above, for which the radical R comprises from 16 to 22 carbon atoms, and more particularly from 16 to 18 carbon atoms.
  • its subject is the composition (A) as defined above, comprising:
  • a subject of the present invention is also a cosmetic, dermopharmaceutical or pharmaceutical formulation comprising, as texturing agent, an effective amount of at least one compound of formula I as defined above.
  • the expression “effective amount” means an amount representing from about 0.1% to about 5% by weight of the formulation.
  • the cosmetic formulation is usually in the form of an aqueous solution, a dilute alcoholic solution or a simple or multiple emulsion, such as a water-in-oil (W/O), oil-in-water (O/W) or water-in-oil-in-water (W/O/W) emulsion, or a dispersion of liposomes or of aminosomes.
  • W/O water-in-oil
  • O/W oil-in-water
  • W/O/W water-in-oil-in-water
  • creams examples which may be mentioned are creams, milks, lotions, antisun emulsions, cosmetic wipes, gels such as shower gels or cream-gels, oils, soaps, liquid soaps, syndets, intimate-hygiene products, shampoos, make-up powders and mascaras.
  • gels such as shower gels or cream-gels, oils, soaps, liquid soaps, syndets, intimate-hygiene products, shampoos, make-up powders and mascaras.
  • a subject of the invention is also the use of a composition (A) as defined above, to prepare a cosmetic, dermopharmaceutical or pharmaceutical formulation.
  • This formulation is prepared according to the methods known to those skilled in the art which are suitable for the desired type of formulation, by combining composition (A) with the usual cosmetic active agents and excipients.
  • the compounds of formula (I) are compatible with most known excipients, whether this is, for example, with reverse latices such as the compounds sold under the names SepigelTM 305, sepigelTM 501, SepigelTM 502, SimulgelTM 600, SiMulgelTM A or SimulgelTM EG, or with the compositions sold under the names MontanovTM 68, MontanovTM 14, MontanovTM 82, MontanovTM 202 or SepigelTM N and described, for example, in the patent applications published under the numbers WO 92/02778, WO 95/13863, WO 96/37285, WO 98/22207 or WO 98/47610.
  • a composition comprising about 45% of palmitoylproline, from 10% to 15% of N-palmitoylglutamic acid, from 10% to 15% of N-palmitoylsarcosine and about 30% of palmitic acid is prepared.
  • a cream-gel (I) is prepared containing, as texturing agent, 3% of the composition prepared in paragraph a) and, as thickener, 3.5% of SepigelTM 305, and a cream-gel (II) containing, as thickener, 3.5% of SepigelTM 305 and containing no texturing agent.
  • the panel assessed the ease of uptake.
  • the panel assessed the ease of spreading, the melting nature, the sensation of freshness, the softness of the product, the absence of a greasy sensation of the product and the speed of penetration.
  • the panel assessed the odour on the skin, the sheen of the skin, the sticky aspect on the skin, the softness of the skin and the presence of residue.
  • composition A The cosmetic formulations below were prepared using the composition prepared in paragraph a) of Example 1 (referred to hereinbelow as composition A):
  • Cyclomethicone 10% Composition A: 3% Sepigel ® 502: 0.8% Montanov ® 68: 2% Stearyl alcohol: 1.5% Preserving agent: 0.65% Lysine: 0.025% EDTA (disodium salt): 0.05% Xanthan gum: 0.2% Glycerol: 3% Water: qs 100%
  • Cyclomethicone 10% Composition A: 3% Sepigel ® 502: 0.8% Montanov ® 68: 2% Perfluoropolymethyl iso- 0.5% propyl ether: Stearyl alcohol: 1.5% Preserving agent: 0.65% Lysine: 0.025% EDTA (disodium salt): 0.05% Pemulen ® TR: 0.2% Glycerol: 3% Water: qs 100%
  • FORMULA Composition A 1% Sepigel TM 502: 2% Fragrance 0.06% Sodium pyrrolidonecarboxylate: 0.2% Dow Corning TM 245 fluid: 2.0% Water: qs 100%
  • Composition A 5% Sepigel TM 501: 5% Ethanol: 30% Menthol: 0.1% Caffeine: 2.5% Extract of Ruscus: 2% Extract of English ivy: 2% Sepicide TM HP: 1% Water: qs 100%
  • composition A 3% Sepigel TM 305: 2% Lipacid TM C8G: 0.5% Montanov TM 202: 0.3% Phytosqualane: 5% Cyclomethicone/polymethyl cyclosiloxane: 10% Sepicide TM HB: 0.2% Water: qs 100%
  • Composition A 3% Sepigel TM 305: 0.7% Simulsol TM 165: 5% Capric caprylic triglyceride: 5% Sepicide TM HB: 0.3% Sepicide TM CI: 0.2% Water: qs 100%
  • Composition A 3% Simulgel TM 600: 2% Isohexadecane 5% Borage oil: 1% Sepicide TM HB: 0.3% Sepicide TM CI: 0.2% Fragrance: 0.1% Water: qs 100%
  • Composition A 3% Sepigel TM 502: 4% Cyclomethicone and dimethiconol: 5% Lanol TM 189: 5% Sepicide TM HS: 0.3% Sepicide TM CI: 0.2% Fragrance: 0.1% Water: qs 100%
  • composition A 3% Sepigel TM 305: 4% Isostearyl isostearate: 5% Micropearl TM M305: 1% Glycerol: 10% Sepicide TM HB: 0.3% Sepicide TM CI: 0.2% Fragrance: 0.2% Water: qs 100%
  • Composition A 3% DHA: 1% Sepigel TM 305: 2% Montanov TM 202: 3% Sweet almond oil: 7% Dimethicone: 3% Fragrance 0.1% Sepifilm TM HB: 0.3% Sepifilm TM CI: 0.2% Water qs 100%
  • Viscosity 15,000 mPa.s (Brookfield LV M3, 6 rpm)
  • Viscosity 35,200 mPa.s (Brookfield LV M4, 6 rpm)
  • MontanovTM 68 cetearyl glucoside is a self-emulsifying composition as described in WO 92/06778, sold by the company SEPPIC.
  • SepigelTM 502 is a thickener based on acrylamide copolymers, sold by the company SEPPIC.
  • PemulenTM TR is an acrylic polymer sold by Goodrich.
  • MicropearlTM M 100 is an ultrafine powder which feels very soft and has a matt effect, sold by the company Matsumo,
  • SepicideTM CI imidazolineurea
  • SEPPIC Streporin
  • SimulsolTM 165 (glyceryl stearate/PEG-100 stearate) is a self-emulsifying composition sold by the company SEPPIC.
  • LanolTM 1688 is an emollient ester with a non-greasy effect, sold by the company SEPPIC.
  • LanolTM 14M and Lanoim S are consistency factors sold by the company SEPPIC.
  • SepicideTM HB which is a mixture of phenoxyethanol, methyl paraben, ethyl paraben, propyl paraben and butyl paraben, is a preserving agent sold by the company SEPPIC.
  • MonteineTM CA is a moisturizer sold by the company SEPPIC.
  • SchercemolTM OP is an emollient ester with a non-greasy effect.
  • LanolTM P is an additive with a stabilizing effect, sold by the company SEPPIC.
  • ParsolTM MCX is octyl para-methoxycinnamate, sold by the company Givaudan.
  • SepiperlTM N is a nacreous agent sold by the company SEPPIC, based on a mixture of alkyl polyglucosides such as those described in WO 95/138063.
  • MicropearlTM SOL is a mixture of microparticles containing squalane which is released under the action of massaging; it is sold by the company Matsumo.
  • LanolTM 99 is isononyl isononanoater sold by the company SEPPIC.
  • LanolTM 37T is glyceryl triheptanoate, sold by the company SEPPIC.
  • SolagumTM L is a carrageenan sold by the company SEPPIC.
  • MarcolTM 82 is a liquid paraffin sold by the company Esso.
  • LanolTM 84D is dioctyl malate, sold by the company SEPPIC.
  • Parsol NOXTM and EusolexTM 4360 are two sunscreens sold by the companies Givaudan and Merck, respectively.
  • Dow CorningTM 245 fluid is cyclomethicone, sold by the company Dow Corning.
  • MontanovTM 202 (arachidyl glucoside/behenyl alcohol) is a self-emulsifying composition as described in WO 92/06778, sold by the company SEPPIC.
  • LipacidTM C8G (octanoylglycine) is sold by the company SEPPIC.
  • ProtealTM Oat is a mixture of N-lauroyl (oligo)amino acids obtained from oat protein.
  • SimulgelTM 600 is a thickener based on acrylamide copolymers, sold by the company SEPPIC.
  • LanolTM 189 is an ester with a rich, creamy feel, sold by the company SEPPIC.
  • MicropearlTM M305 is a crosslinked polymethyl methacrylate copolymer sold by the company Matsumo; it gives a matt appearance when it is used in large amount (about 10%).
  • SimulgelTM M EG is an emulsifying thickener in the form of a reverse latex based on a copolymer of sodium acrylate and sodium acryloyldimethyltaurate in isohexadecane with sorbitan oleate, sold by the company SEPPIC.
  • SimulgelTM A is a thickener in the form of a reverse latex based on neutralized acrylic acid homopolymer in isohexadecane with 40E0 ethoxylated castor oil, sold by the company SEPPIC.
  • PecosilTM PS100 is a dimethicone copolyol phosphate sold by the company Phoenix.

Abstract

Use of at least one compound of formula (I);
Figure US06440435-20020827-C00001
in which R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid, comprising from 16 to 22 carbon atoms,
Figure US06440435-20020827-C00002
represents the characterizing chain or cyclic radical of an amino acid, R2 represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or the topically acceptable salts thereof, as texturing agents, it being understood that the amino acid characterized by R1 is not lysine, hydroxylysine or arginine. Novel compositions. Application in cosmetics.

Description

This application is a division of U.S. application Ser. No. 09/470,516, filed Dec. 22, 1999.
FIELD OF THE INVENTION
The present invention relates to a novel use of N-acylamino acid derivatives. These compounds, for example those described in the international patent applications published under the numbers WO 92/20647, WO 92/21318, WO 94/26694, WO 94/27561 and WO 98/09611, are, in particular on account of their antimicrobial and antielastic activity, used as active agents in formulations for topical use. Such cosmetic, dermopharmaceutical or pharmaceutical formulations intended to care for the skin or mucous membranes must be easy to take up with the fingers before they are applied; when they are applied on the skin or on mucous membranes, they must spread easily, penetrate quickly and melt in well while at the same time affording sensations of freshness and softness, without being perceived as greasy or oily, and, after they have been applied to the skin or mucous membranes, they must not give rise to any sheen on the skin, or any unpleasant odour, or appear sticky; however, the sensations of softness and freshness resulting from their application must remain.
SUMMARY OF THE INVENTION
Now, in order to obtain a sensory profile which satisfies a formulation, it is often necessary to include texturing agents therein, which are compounds or mixtures of compounds capable of improving the rheological and sensory properties of the formulation. The applicant has found, unexpectedly, that N-acylamino acid derivatives can be used effectively as texturing agents for cosmetic, dermopharmaceutical or pharmaceutical formulations.
Accordingly, a subject of the invention is the use of at least one compound of formula (I):
Figure US06440435-20020827-C00003
in which R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid, the fragment R—CO comprises from 12 to 22 carbon atoms and more particularly from 16 to 22 carbon atoms,
Figure US06440435-20020827-C00004
represents the characterizing chain or cyclic radical of an amino acid, R2 represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or the topically acceptable salts thereof, as texturing agents, it being understood that the amino acid characterized by R1 is not lysine, hydroxylysine or
The expression “topically acceptable salt” means any salt of the acid of formula (I) which is biologically acceptable for the skin and/or mucous membranes, i.e., any salt which can in particular adjust the pH of the composition to a value of between 3 and 8 and preferably approximately equal to 5, which is a pH in the region of the skin's pH. Examples of such salts are, in particular, alkali metal salts, such as sodium, potassium or lithium salts, alkaline-earth metal salts, such as calcium, magnesium or strontium salts; they can also be metal salts such as divalent zinc, copper or manganese salts or alternatively trivalent iron, lanthanum, cerium or aluminium salts. The compound of formula (I) present in the composition which is the subject of the present invention can be in free acid form or in partially or totally salified form. The expression “characterizing chain” used in the context of the present patent application denotes the main chain of the fatty acid or of the amino acid under consideration. Thus, for a fatty acid corresponding to the general formula R—COOH, the characterizing chain will be the chain represented by R. The linear or branched, saturated or unsaturated radical R represents a radical comprising from 11 to 21 carbon atoms, chosen, for example, from undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, uneicosyl, docosyl, heptadecenyl, eicosenyl, uneicosenyl and heptadecadienyl radicals.
A subject of the invention is, more particularly, the use as defined above, for which, in formula (I), the fragment R—CO represents in particular one of the following radicals: dodecanoyl (lauroyl), tetradecanoyl (myristyl), hexadecanoyl (palmitoyl), octadecanoyl (stearyl), eicosanoyl (arachidoyl), docosanoyl (behenoyl), octadecenoyl (oleyl), eicosenoyl (gadoloyl), docosenoyl (erucyl) or octadecadienoyl (linolenoyl). For an amino acid represented by the general formula;
HN(R2)—CHR1—COOH,
it will be characterized by the definition of R1; for an amino acid represented by the general formula:
Figure US06440435-20020827-C00005
it will be characterized by the definition of the cyclic radical:
Figure US06440435-20020827-C00006
In the context of the present invention, the chain or the cyclic radical characterizing the amino acid are chosen from those of glycine, alanine, serine, aspartic acid, glutamic acid, valine, threonine, proline, leucine, phenylalanine, isoleucine, histidine, tyrosine, tryptophan, asparagine, cysteine, cystine, methionine, hydroxyproline, ornithine and sarcosine. A subject of the invention is, more particularly, the use as described above for which, in formula (I), the chain or the cyclic radical characterizing the amino acid are chosen from those of glycine, proline, glutamic acid and sarcosine.
The expression “at least one compound of formula (I)” means that the invention can be carried out with one or more of these compounds. The expression “or more of these compounds” means:
either a mixture of compounds of formula (I), resulting from the condensation of a single amino acid with a mixture of fatty acids, and more particularly a mixture of fatty acids of natural origin, or a mixture of compounds of formula (I) resulting from the condensation of a mixture of amino acids with a single fatty acid, or a mixture of compounds of formula (I) resulting from the condensation of a mixture of amino *acids with a mixture of fatty acids, and more particularly with a mixture of fatty acids of natural origin. The mixtures of fatty acids of natural origin which can be used advantageously for the preparation of the compounds of formula (I) are, in particular, those derived from coconut oil, palm kernel oil, palm oil, soybean oil, rapeseed oil, bovine tallow, spermaceti oil, herring oil or castor oil.
According to a very specific aspect of the present invention, its subject is the use, as described above, of a mixture comprising at least one compound of formula (Ia) corresponding to formula (I), in which the cyclic radical characterizing the amino acid is that of praline, and at least one compound of formula (Ib) corresponding to formula (I) in which the characterizing chain of the amino acid is that of glutamic acid, and optionally at least one compound of formula (Ic) corresponding to formula (I) in which R2 represents a methyl radical and R1 represents the characterizing chain of sarcosine; as an example of such a use, mention may be made of the use of the mixture comprising N-palmitoylproline and N-palmitoylglutamic acid or the sodium or magnesium salts thereof or the use of the mixture comprising N-palmitoylproline, N-palmitoylglutamic acid and N-palmitoylsarcosine or the sodium or magnesium salts thereof.
According to another very specific aspect of the present invention, its subject is the use, as described above, of a composition comprising N-cocoylglycine or one of the topically acceptable salts thereof.
The compounds of formula (I) are obtained by the methods known to those skilled in the art and described in particular in the international patent applications published under the numbers WO 92/20647, WO 92/21318, WO 94/26694, WO 94/27561 and WO 98109611.
A subject of the invention is also a composition (A) comprising;
a) from 10% to 95% by weight, and more particularly from 60% to 80% by weight, of at least one compound of formula (I):
Figure US06440435-20020827-C00007
 in which R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid comprising from 12 to 22 carbon atoms,
Figure US06440435-20020827-C00008
 represents the chain or the cyclic radical characterizing the amino acid, chosen from those of glycine, alanine, serine, aspartic acid, glutamic acid, valine, threonine, proline, leucine, phenylalanine, isoleucine, histidine, tyrosine, tryptophan, asparagine, cysteine, cystine, methionine, hydroxyproline, ornithine and sarcosine, R, represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or one of the topically acceptable salts thereof, and R2 represents a hydrogen atom or an alkyl radical comprising from 1 to 3 carbon atoms, or one of the topically acceptable salts thereof, and
b) from 90% to 5% by weight of at least one compound of formula (II)
R—CO—OH,
or one of the topically acceptable salts thereof.
A subject of the invention is, more particularly, a composition (A) as defined above, for which the radical R comprises from 16 to 22 carbon atoms, and more particularly from 16 to 18 carbon atoms. According to one very specific aspect of the present invention, its subject is the composition (A) as defined above, comprising:
from 30% to 50% by weight of palmitoylproline,
from 5% to 25% by weight of N-palmitoylglutamic acid,
from 0% to 25% by weight of N-palmitoylsarcosine and
from about 5% to about 40% by weight of palmitic acid.
According to another very specific aspect of the present invention, its subject is the composition (A) as defined above, comprising:
from 30% to 70% by weight of cocoylglycine,
from 0% to 25% by weight of N-cocoylsarcosine and
from about 5% to about 45% by weight, and more particularly from 5% to about 20% by weight, of the mixture of fatty acids derived from coconut oil.
A subject of the present invention is also a cosmetic, dermopharmaceutical or pharmaceutical formulation comprising, as texturing agent, an effective amount of at least one compound of formula I as defined above. In the context of the present invention, the expression “effective amount” means an amount representing from about 0.1% to about 5% by weight of the formulation.
The cosmetic formulation is usually in the form of an aqueous solution, a dilute alcoholic solution or a simple or multiple emulsion, such as a water-in-oil (W/O), oil-in-water (O/W) or water-in-oil-in-water (W/O/W) emulsion, or a dispersion of liposomes or of aminosomes. The term “aminosome” denotes a type of liposome formed by amphiphilic amino acid derivatives. Examples which may be mentioned are creams, milks, lotions, antisun emulsions, cosmetic wipes, gels such as shower gels or cream-gels, oils, soaps, liquid soaps, syndets, intimate-hygiene products, shampoos, make-up powders and mascaras.
A subject of the invention is also the use of a composition (A) as defined above, to prepare a cosmetic, dermopharmaceutical or pharmaceutical formulation. This formulation is prepared according to the methods known to those skilled in the art which are suitable for the desired type of formulation, by combining composition (A) with the usual cosmetic active agents and excipients.
The compounds of formula (I) are compatible with most known excipients, whether this is, for example, with reverse latices such as the compounds sold under the names Sepigel™ 305, sepigel™ 501, Sepigel™ 502, Simulgel™ 600, SiMulgel™ A or Simulgel™ EG, or with the compositions sold under the names Montanov™ 68, Montanov™ 14, Montanov™ 82, Montanov™ 202 or Sepigel™ N and described, for example, in the patent applications published under the numbers WO 92/02778, WO 95/13863, WO 96/37285, WO 98/22207 or WO 98/47610.
The examples which follow illustrate the invention without, however, limiting it.
DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1 Sensory Profile of Composition According to the Invention
a) A composition comprising about 45% of palmitoylproline, from 10% to 15% of N-palmitoylglutamic acid, from 10% to 15% of N-palmitoylsarcosine and about 30% of palmitic acid is prepared.
b) A cream-gel (I) is prepared containing, as texturing agent, 3% of the composition prepared in paragraph a) and, as thickener, 3.5% of Sepigel™ 305, and a cream-gel (II) containing, as thickener, 3.5% of Sepigel™ 305 and containing no texturing agent.
c) The sensory test was carried out on a panel of 15 individuals; these individuals assessed and compared the qualities of the two cream-gels in the following three situations:
1) Assessment of the Uptake of the Cream-gel with the Fingers in Order Subsequently to Spread it on the Skin
The panel assessed the ease of uptake.
2) Assessment of the Application of the Cream-gel onto the Skin
The panel assessed the ease of spreading, the melting nature, the sensation of freshness, the softness of the product, the absence of a greasy sensation of the product and the speed of penetration.
3) Assessment After Application
The panel assessed the odour on the skin, the sheen of the skin, the sticky aspect on the skin, the softness of the skin and the presence of residue.
The results are given in the table below in the following manner:
positive assessments or negative assessments when at least two thirds of the members are of the same opinion:
undifferentiated assessment (indicated by “idem”) when less than two thirds of the members are of the same opinion:
Cream-gel (I) Cream-gel (II)
Invention Comparison
Ease of uptake Easier Less easy
Ease of spreading Easier Less easy
Melting nature Melts more Melts less easily
easily
Sensation of Melts more
freshness easily
Softness Softer Less soft
Greasy sensation Less greasy More greasy
Penetration Faster Slower
Odour on the skin
Sheen of the skin Less shiny More shiny
Stickiness on the
skin
Softness of the skin Softer Less soft
Persistence More persistent Less persistent
These results show that the presence of compounds of formula (I) in a cosmetic formulation markedly improve the sensory profile of the said formulation by improving its tactile properties.
Examples of Cosmetic Formulations EXAMPLES 2 TO 37
The cosmetic formulations below were prepared using the composition prepared in paragraph a) of Example 1 (referred to hereinbelow as composition A):
EXAMPLE 2
Care Cream
Cyclomethicone:   10%
Composition A:    3%
Sepigel ® 502:  0.8%
Montanov ® 68:    2%
Stearyl alcohol:  1.5%
Preserving agent:  0.65%
Lysine: 0.025%
EDTA (disodium salt):  0.05%
Xanthan gum:  0.2%
Glycerol:    3%
Water: qs 100%
EXAMPLE 3
Care Cream
Cyclomethicone:   10%
Composition A:    3%
Sepigel ® 502:  0.8%
Montanov ® 68:    2%
Perfluoropolymethyl iso-  0.5%
propyl ether:
Stearyl alcohol:  1.5%
Preserving agent:  0.65%
Lysine: 0.025%
EDTA (disodium salt):  0.05%
Pemulen ® TR:  0.2%
Glycerol:    3%
Water: qs 100%
EXAMPLE 4
After-shave Balm
FORMULA
A Composition A:   3%
Sepigel ™ 502:  1.5%
Water: qs 100%
B Micropearl ™ 100:  5.0%
Sepicide ™ CI: 0.50%
Fragrance: 0.20%
95° ethanol: 10.0%
PROCEDURE
Add B to A.
EXAMPLE 5
Satin Emulsion for the Body
FORMULA
A Simulsol ™ 165:  5.0%
Lanol ™ 1688: 8.50%
Karite butter:   2%
Liquid paraffin:  6.5%
Lanol ™ 14M:   3%
Lanol ™ S:  0.6%
Water: 66.2%
C Micropearl ™ M 100:   5%
D Composition A:   3%
Sepigel ™ 502:   3%
E Sepicide ™ CI:  0.3%
Sepicide ™ HB:  0.5%
Monteine ™ CA:   1%
Fragrance: 0.20%
Vitamin E acetate: 0.20%
Sodium pyrrolidone- 1% (moisturizer)
carboxylate:
Procedure
Add C to B, emulsify a in A at 70° C. and then add D at 60° C., followed by E at 30° C.
EXAMPLE 6
Body Milk
FORMULA
A Simulsol ™ 165:  5.0%
Lanol ™ 1688: 12.0%
Lanol ™ 14M:  2.0%
Cetyl alcohol:  0.3%
Schercemol ™ OP:   3%
B Water:  100%
C Composition A:   3%
Sepigel ™ 502: 0.35%
D Sepicide ™ CI:  0.2%
Sepicide ™ HB:  0.5%
Fragrance: 0.20%
Procedure
Emulsify B in A at about 75° C.; add C at about 60° C., followed by D at about 30° C.
EXAMPLE 7
O/W Cream
FORMULA
A Simulsol ™ 165:  5.0%
Lanol ™ 1688: 20.0%
Lanol ™ P:  1.0%
B Water qs 100%
C Composition A:   3%
Sepigel ™ 502;  2.5%
D Sepicide ™ CI: 0.20%
Sepicide ™ HB: 0.30%
Procedure
Introduce B into A at about 75° C.; add C at about 60° C., followed by D at about 45° C.
EXAMPLE 8
Non-greasy Antisun Gel
FORMULA
A Composition A:   3%
Sepigel ™ 502:  0.8%
Water:   30%
B Sepicide ™ CI: 0.20%
Speicide ™ HB: 0.30%
Fragrance: 0.10%
C Dye: qs
Water:   30%
D Micropearl ™ M 100: 3.00%
Water: qs 100%
E Silicone oil:  2.0%
Parsol ™ MCX: 5.00%
Procedure
Introduce B into A; add C, then D and then E.
EXAMPLE 9
Antisun Milk
FORMULA
A Sepiperl ™ N:  3.0%
Sesame oil:  5.0%
Parsol ™ MCX:  5.0%
λ-Carrageenan: 0.10%
B Water: qs 100%
C Composition A:   3%
Sepigel ™ 502:  0.8%
D Fragrance: qs
Preserving agent: qs
Procedure
Emulsify B in A at 75° C., then add C at about 60° C., followed by D at about 30° C. and adjust the pH if necessary.
EXAMPLE 10
Massage Gel
FORMULA
A Composition A:   3%
Sepigel ™ 501:  3.5%
Water: 20.0%
B Dye: 2 drops/100 g
Water: qs
C Alcohol:   10%
Menthol: 0.10%
D Silicone oil:  5.0%
Procedure
Add B to A; then add C to the mixture, followed by D.
EXAMPLE 11
Massage Care Gel
FORMULA
A Composition A:   3%
Sepigel ™ 502:  3.0%
Water:   30%
B Sepicide ™ CI: 0.20%
Sepicide ™ HB: 0.30%
Fragrance: 0.05%
C Dye: qs
Water: qs 100%
D Micropearl ™ SQL: 5.00%
Lanol ™ 1688:   2%
Procedure
Prepare A; add B, then C and then D.
EXAMPLE 12
Sunburn Gel
FORMULA
A Composition A:   3%
Sepigel ™ 502:   4%
Water:   30%
B Elastine HPM:  5.0%
C Micropearl ™ M 100:   3%
Water   5%
D Sepicide ™ CI:  0.2%
Sepicide ™ HB:  0.3%
Fragrance: 0.06%
50% sodium pyrrolidonecarboxylate:   1%
Water: qs 100%
Procedure
Prepare A; add B. then C and then D.
EXAMPLE 13
Body Milk
FORMULA
A Sepiperl ™ N:  3.0%
Glyceryl triheptonate: 10.0%
Water: qs 100%
C Composition A:  1.5%
Sepigel ™ 502:  1.0%
D Fragrance: qs
Preserving agent: qs
Procedure
Melt A at about 75° C. Emulsify B in A at 75° C. and then add C at about 60° C., followed by D.
EXAMPLE 14
Maka-up-removing Emulsion Containing Sweet Almond Oil
FORMULA
Montanov ™ 68:   5%
Sweet almond oil:   5%
Water: qs 100%
Composition A:   1%
Sepigel ™ 502: 0.3%
Glycerol:   5%
Preserving agent: 0.2%
Fragrance: 0.3%
EXAMPLE 15
Moisturizing Cream for Greasy Skin
FORMULA
Montanov ™ 68:   5%
Cetylstearyl octanoate:   8%
Octyl palmitate:   2%
Water: qs 100%
Composition A:   2%
Sepigel ™ 502: 0.6%
Micropearl ™ M100: 3.0%
Mucopolysaccharides:   5%
Sepicide ™ HB: 0.8%
Fragrance: 0.3%
EXAMPLE 16
Alcohol-free Soothing After-shave Balm
FORMULA
Lanol ™ 99:   2%
Sweet almond oil: 0.5%
Water: qs 100%
Composition A:   3%
Sepigel ™ 501:   3%
Sepicide ™ XB: 0.3%
Sepicide ™ CI: 0.2%
Fragrance: 0.4%
EXAMPLE 17
Cream Containing HAAs for Sensitive Skin
FORMULA
Lanol ™ 99:   2%
Montanov ™ 68:  5.0%
Water: qs 100%
Composition A: 0.1 to 5%
Sepigel ™ 501:  1.5%
Gluconic acid: 1.50%
Triethylamine:  0.9%
Sepicide ™ HB:  0.3%
Sepicide ™ CI:  0.2%
Fragrance:  0.4%
EXAMPLE 18
After-sun Soothing Care Product
FORMULA
Lanol ™ 99: 10.0%
Water: qs 100%
Composition A:   3%
Sepigel ™ 502:  2.5%
Sepicide ™ HB:  0.3%
Sepicide ™ CI:  0.2%
Fragrance  0.4%
Dye: 0.03%
EXAMPLE 19
Make-up-Removing Milk
FORMULA
Sepiperl ™ N:   3%
Primol ™ 352: 8.0%
Sweet almond oil:   3%
Water: qs 100%
Composition A:   2%
Sepigel ™ 502: 0.8%
Preserving agent: 0.2%
EXAMPLE 20
Body Milk
FORMULA
Sepiperl ™ N:  3.5%
Lanol ™ 37T:  8.0%
Solagum ™ L: 0.05%
Water: qs 100%
Benzophenone:  2.0%
Dimethicone 350 cPs: 0.05%
Composition A:   2%
Sepigel ™ 502:  0.8%
Preserving agent:  0.2%
Fragrance:  0.4%
EXAMPLE 21
Liquid Emulsion at Alkaline pH
Marcol ™ 82:  5.0%
NaOH: 10.0%
Water: qs 100%
Composition A:   4%
Sepigel ™ 502:  1.5%
EXAMPLE 22
Liquid Foundation
FORMULA
Simulsol ™ 165:  5.0%
Lanol ™ 84D:  8.0%
Lanol ™ 99:  5.0%
Water: qs 100%
Mineral pigments and fillers: 10.0%
Composition A:   3%
Sepigel ™ 502:  1.2%
Preserving agent:  0.2%
Fragrance:  0.4%
EXAMPLE 23
Antisun Milk
FORMULA
Sepiperl ™ N:  3.5%
Lanol ™ 37T: 10.0%
Parsol NOX ™:  5.0%
Eusolex ™ 4360:  2.0%
Water: qs 100%
Composition A:   3%
Sepigel ™ 502:  1.8%
Preserving agent:  0.2%
Fragrance:  0.4%
EXAMPLE 24
Gel for the Contour of the Eyes
FORMULA
Composition A:   1%
Sepigel ™ 502:   2%
Fragrance 0.06%
Sodium pyrrolidonecarboxylate:  0.2%
Dow Corning ™ 245 fluid:  2.0%
Water: qs 100%
EXAMPLE 25
Leave-on Care Composition
FORMULA
Composition A:   3%
Sepigel ™ 502: 1.5%
Fragrance: qs
Preserving agent: qs
Dow Corning ™ X2 8360: 5.0%
Dow Corning ™ Q2 1401:  15%
Water: qs 100%
EXAMPLE 26
Slendering Gel
Composition A:   5%
Sepigel ™ 501:   5%
Ethanol:  30%
Menthol: 0.1%
Caffeine: 2.5%
Extract of Ruscus:   2%
Extract of English ivy:   2%
Sepicide ™ HP:   1%
Water: qs 100%
EXAMPLE 27
Comfort Cream for Sensitive Skin
Composition A:   3%
Sepigel ™ 305:   2%
Lipacid ™ C8G: 0.5%
Montanov ™ 202: 0.3%
Phytosqualane:   5%
Cyclomethicone/polymethyl cyclosiloxane:  10%
Sepicide ™ HB: 0.2%
Water: qs 100%
EXAMPLE 28
Soothing Care Product
Composition A:   3%
Sepigel ™ 305: 0.7%
Simulsol ™ 165:   5%
Capric caprylic triglyceride:   5%
Sepicide ™ HB: 0.3%
Sepicide ™ CI: 0.2%
Water: qs 100%
EXAMPLE 29
Cream-gel for Sensitive Skin
Composition A:   3%
Simulgel ™ 600:   2%
Isohexadecane   5%
Borage oil:   1%
Sepicide ™ HB: 0.3%
Sepicide ™ CI: 0.2%
Fragrance: 0.1%
Water: qs 100%
EXAMPLE 30
After-sun Soothing Care Product
Composition A:   3%
Sepigel ™ 502:   4%
Cyclomethicone and dimethiconol:   5%
Lanol ™ 189:   5%
Sepicide ™ HS: 0.3%
Sepicide ™ CI: 0.2%
Fragrance: 0.1%
Water: qs 100%
EXAMPLE 31
Soothing Gel for the Hands
Composition A:   3%
Sepigel ™ 305:   4%
Isostearyl isostearate:   5%
Micropearl ™ M305:   1%
Glycerol:  10%
Sepicide ™ HB: 0.3%
Sepicide ™ CI: 0.2%
Fragrance: 0.2%
Water: qs 100%
EXAMPLE 32
Moisturizing Cream for Sensitive Skin
Montanov ™ 68:   7%
Isostearyl isostearate:   5%
Dimethicone:  10%
Water: qs 100%
Composition A:   2%
Sepigel ™ 305:   1%
Sepicide ™ HB: 0.3%
Sepicide ™ CI: 0.2%
Fragrance: 0.2%
EXAMPLE 33
Self-tanning Care Product
Composition A:   3%
DHA:   1%
Sepigel ™ 305:   2%
Montanov ™ 202:   3%
Sweet almond oil:   7%
Dimethicone:   3%
Fragrance 0.1%
Sepifilm ™ HB: 0.3%
Sepifilm ™ CI: 0.2%
Water qs 100%
EXAMPLE 34
Compact Powder
Talc: 57%
Polymethylenemethacrylate: 15%
Dimethicone: 15%
Zinc stearate:  5%
Isononylisononanoate:  5%
Composition A:  3%
Colorants: qs
EXAMPLE 35
Cream Gel
FORMULA
A Water:   10%
Butylene glycol:   4%
PEG-400:   4%
Titanium dioxide:   2%
Yellow iron oxide:  0.8%
Red iron oxide:  0.3%
Black iron oxide: 0.05%
Pecosil ™ PS100:  1.5%
B Isononyl isononanoate:   4%
Caprylic capric triglyceride:   4%
Composition A:   1%
Simulgel ™ A:   3%
Cyclomethicone:   4%
C Water: qs 100%
Micropearl ™ M305:   2%
Tetrasodium EDTA: 0.05%
D Sepicide ™ HB:  0.3%
Sepicide ™ CI:  0.2%
Fragrance:  0.2%
Procedure
Mix together B and C to form the gel. Add A, followed by D.
Properties
Appearance: fluid cream; pH=7;
Viscosity 15,000 mPa.s (Brookfield LV M3, 6 rpm)
EXAMPLE 36
Anti-wrinkle Complex
FORMULA
A Water:   10%
Butylene glycol:   4%
PEG-400:   4%
Titanium dioxide:   2%
Yellow iron oxide:  0.8%
Red iron oxide:  0.3%
Black iron oxide: 0.05%
Proteol ™ Oat:  1.5%
B Isononyl isononanoate:   4%
Caprylic/capric triglycerride:   4%
Composition A:   1%
Simulgel ™ A:   3%
Cyclomethicone:   4%
C Water: qs 100%
Micropearl ™ M305:   2%
Tetrasodium EDTA: 0.05%
D Sepicide ™ HB:  0.3%
Sepicide ™ CI:  0.2%
Fragrance:  0.2%
Procedure
Mix together B and C to form the gel. Add A, followed by D.
Properties
Appearance: cream; pH=7.2;
Viscosity 35,200 mPa.s (Brookfield LV M4, 6 rpm)
EXAMPLE 37
Matt-effect Emulsion
FORMULA
A Composition A: 0.5%
Simugel ™ EG:   1%
Dimethicone:   5%
B Water: qs 100%
Micropearl ™ M305:  10%
Butylene glycol:   5%
C Sepicide ™ HB: 0.5%
Fragrance: 0.2%
Procedure
Mix together A and B to form the gel, Add C.
Properties
Appearance: fluid formula; pH=5.7
Visscosity 4700 mPa.s (Brookfield LV M3, 6 rpm)
The commercial names given above have the following definitions:
Montanov™ 68 (cetearyl glucoside) is a self-emulsifying composition as described in WO 92/06778, sold by the company SEPPIC.
Sepigel™ 502 is a thickener based on acrylamide copolymers, sold by the company SEPPIC.
Pemulen™ TR is an acrylic polymer sold by Goodrich.
Micropearl™ M 100 is an ultrafine powder which feels very soft and has a matt effect, sold by the company Matsumo,
Sepicide™ CI, imidazolineurea, is a preserving agent sold by the company SEPPIC.
Simulsol™ 165 (glyceryl stearate/PEG-100 stearate) is a self-emulsifying composition sold by the company SEPPIC.
Lanol™ 1688 is an emollient ester with a non-greasy effect, sold by the company SEPPIC.
Lanol™ 14M and Lanoim S are consistency factors sold by the company SEPPIC.
Sepicide™ HB, which is a mixture of phenoxyethanol, methyl paraben, ethyl paraben, propyl paraben and butyl paraben, is a preserving agent sold by the company SEPPIC.
Monteine™ CA is a moisturizer sold by the company SEPPIC.
Schercemol™ OP is an emollient ester with a non-greasy effect.
Lanol™ P is an additive with a stabilizing effect, sold by the company SEPPIC.
Parsol™ MCX is octyl para-methoxycinnamate, sold by the company Givaudan.
Sepiperl™ N is a nacreous agent sold by the company SEPPIC, based on a mixture of alkyl polyglucosides such as those described in WO 95/138063.
Micropearl™ SOL is a mixture of microparticles containing squalane which is released under the action of massaging; it is sold by the company Matsumo.
Lanol™ 99 is isononyl isononanoater sold by the company SEPPIC.
Lanol™ 37T is glyceryl triheptanoate, sold by the company SEPPIC.
Solagum™ L is a carrageenan sold by the company SEPPIC.
Marcol™ 82 is a liquid paraffin sold by the company Esso.
Lanol™ 84D is dioctyl malate, sold by the company SEPPIC.
Parsol NOX™ and Eusolex™ 4360 are two sunscreens sold by the companies Givaudan and Merck, respectively.
Dow Corning™ 245 fluid is cyclomethicone, sold by the company Dow Corning.
Montanov™ 202 (arachidyl glucoside/behenyl alcohol) is a self-emulsifying composition as described in WO 92/06778, sold by the company SEPPIC.
Lipacid™ C8G (octanoylglycine) is sold by the company SEPPIC.
Proteal™ Oat is a mixture of N-lauroyl (oligo)amino acids obtained from oat protein.
Simulgel™ 600 is a thickener based on acrylamide copolymers, sold by the company SEPPIC.
Lanol™ 189 is an ester with a rich, creamy feel, sold by the company SEPPIC.
Micropearl™ M305 is a crosslinked polymethyl methacrylate copolymer sold by the company Matsumo; it gives a matt appearance when it is used in large amount (about 10%).
Simulgel™ M EG is an emulsifying thickener in the form of a reverse latex based on a copolymer of sodium acrylate and sodium acryloyldimethyltaurate in isohexadecane with sorbitan oleate, sold by the company SEPPIC.
Simulgel™ A is a thickener in the form of a reverse latex based on neutralized acrylic acid homopolymer in isohexadecane with 40E0 ethoxylated castor oil, sold by the company SEPPIC.
Pecosil™ PS100 is a dimethicone copolyol phosphate sold by the company Phoenix.

Claims (5)

We claim:
1. The method of improving the texture of a cosmetic, dermocosmetic or pharmaceutical formulation, which comprises combining at least one cosmetic agent and at least one excipient with an effective amount of a texturing composition; said texturing composition comprising N-cocoyl glycine or one of a topically acceptable salt thereof; said effective amount representing from about 0.1% to about 5% by weight of the formulation.
2. The method according to claim 1, wherein the composition comprises from 30% to 70% by weight of N-cocoyl glycine, from 0% to 25% by weight of N-cocoyl sarcosine and from 5% to 45% by weight of a mixture of fatty acids derived from coconut oil.
3. The method according to claim 2, wherein the composition comprises from 5% to 20% by weight of the mixture of fatty acids derived from coconut oil.
4. A cosmetic, dermocosmetic or pharmaceutical formulation comprising as a texturing agent from about 0.1% to about 5% by weight of a composition comprising from 30% to 70% by weight of N-cocoyl glycine, from 0% to 25% by weight of N-cocoyl sarcosine and from 5% to 45% by weight of a mixture of fatty acids derived from coconut oil.
5. The formulation according to claim 4, wherein the composition comprises from 5% to 20% by weight of the mixture of fatty acids derived from coconut oil.
US09/845,199 1998-12-22 2001-05-01 Use of N-acylamino acid compounds as texturing agents Expired - Fee Related US6440435B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/845,199 US6440435B1 (en) 1998-12-22 2001-05-01 Use of N-acylamino acid compounds as texturing agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9816239A FR2787323B1 (en) 1998-12-22 1998-12-22 USE OF N-ACYLATED AMINO ACID COMPOUNDS AS TEXTURING AGENT
FR9816239 1998-12-22
US09/470,516 US6274151B1 (en) 1998-12-22 1999-12-22 Use of n-acylamino acid compounds as texturing agents
US09/845,199 US6440435B1 (en) 1998-12-22 2001-05-01 Use of N-acylamino acid compounds as texturing agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/470,516 Division US6274151B1 (en) 1998-12-22 1999-12-22 Use of n-acylamino acid compounds as texturing agents

Publications (1)

Publication Number Publication Date
US6440435B1 true US6440435B1 (en) 2002-08-27

Family

ID=9534323

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/470,516 Expired - Fee Related US6274151B1 (en) 1998-12-22 1999-12-22 Use of n-acylamino acid compounds as texturing agents
US09/845,199 Expired - Fee Related US6440435B1 (en) 1998-12-22 2001-05-01 Use of N-acylamino acid compounds as texturing agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/470,516 Expired - Fee Related US6274151B1 (en) 1998-12-22 1999-12-22 Use of n-acylamino acid compounds as texturing agents

Country Status (4)

Country Link
US (2) US6274151B1 (en)
EP (1) EP1013266A1 (en)
JP (1) JP2000191426A (en)
FR (1) FR2787323B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019356A1 (en) * 2003-07-25 2005-01-27 The Procter & Gamble Company Regulation of mammalian keratinous tissue using N-acyl amino acid compositions
FR2873575A1 (en) * 2004-07-28 2006-02-03 Miyoshi Kasei Inc Coated powder for use in cosmetics, contains lipoamino acid composition containing N-acyl structure of amino acids e.g. proline, alanine, glycine, aspartic acid and glutamic acid and 12-18C fatty acid, which coats powder
EP1813252A1 (en) * 2006-01-30 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Cosmetic composition for matting the scalp
US20080076720A1 (en) * 2003-03-04 2008-03-27 Sancai Xie Personal care compositions having kinetin or zeatin
KR20110059844A (en) * 2008-09-03 2011-06-07 소시에떼 덱스플로와따시옹 더 쁘로뒤 뿌르 레 엥뒤스트리 쉬미끄, 에스. 에. 페. 페. 이. 세. Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, n-palmitoyl isoleucine, and n-cocoyl alanine as an active agent controlling the proportion of basal keratinocytes of the human skin epidermis and expressing the nuclear form of surviving, and anti-aging cosmetic composition comprising same
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4034509B2 (en) * 2000-10-30 2008-01-16 株式会社資生堂 Skin cosmetics
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
DE10220867A1 (en) 2002-05-10 2003-11-20 Henkel Kgaa Cosmetic compositions with a silicone elastomer and a thickening polymer latex
FR2850866B1 (en) * 2003-02-06 2007-04-20 Seppic Sa MIXTURE OF SELF-REVERSIBLE REVERSE LATEX AND POWDER FOR COSMETIC OR PHARMACEUTICAL USE; USE AS A TEXTURE AGENT
FR2867070B1 (en) * 2004-03-04 2009-07-10 Oreal TRANSPARENT SELF TUNING GEL CONTAINING HYDROSOLUBLE OR HYDRODISPERSIBLE ACRYLAMIDO 2-METHYL PROPANE SULFONIC ACID POLYMER
US9572754B2 (en) 2004-03-04 2017-02-21 L'oreal Transparent self-tanning gels containing a water-soluble/dispersible acrylamido-2-methylpropanesulfonic acid polymer
JPWO2006093311A1 (en) * 2005-03-01 2008-08-07 味の素株式会社 Cleaning composition
US8216554B2 (en) 2005-04-20 2012-07-10 L'oreal Stable transfer-resistant self-tanning gel containing a water-soluble or water-dispersible gelling agent
DE102006008920B3 (en) * 2006-02-21 2007-08-09 Lancaster Group Gmbh Sun protection product, useful in cosmetics e.g. sun cream, comprises volatile, cyclic silicone, non-volatile silicone elastomer, emulsifier, fatty acid-copolymer, organic filter, auxiliary material, carrier material and active agent
FR2908651B1 (en) * 2006-11-21 2012-06-29 Oreal COSMETIC COMPOSITION COMPRISING A PROLINE DERIVATIVE OR SALT THEREFROM
FR2910321B1 (en) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc CREAM GEL COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
FR2910320B1 (en) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc EMULSION COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
CN101578086A (en) * 2007-01-16 2009-11-11 宝洁公司 Cosmetic compositions
JP5527414B2 (en) 2010-07-01 2014-06-18 トヨタ自動車株式会社 Manufacturing method of ceramic laminate
JPWO2012060105A1 (en) 2010-11-05 2014-05-12 日本電気株式会社 Information processing device
WO2012077241A1 (en) 2010-12-06 2012-06-14 L'oreal Powdery cosmetic composition
EP2706972A1 (en) * 2011-05-13 2014-03-19 L'Oréal Powdery cosmetic composition
JP6532646B2 (en) 2013-12-06 2019-06-19 ロレアル Powdery cosmetic composition
WO2017094852A1 (en) * 2015-12-02 2017-06-08 味の素株式会社 Composition for external application
WO2018220916A1 (en) * 2017-06-02 2018-12-06 味の素株式会社 Topical composition
JP7102687B2 (en) * 2017-06-02 2022-07-20 味の素株式会社 External composition
JP6943024B2 (en) * 2017-06-02 2021-09-29 味の素株式会社 Topical composition

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2234399A1 (en) 1972-07-17 1974-01-31 Thomae Gmbh Dr K SKIN PROTECTION PRODUCTS
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
JPS61291700A (en) 1985-06-18 1986-12-22 ライオン株式会社 Foamable skin cleaning composition
WO1992021318A1 (en) 1991-06-03 1992-12-10 Givaudan-Lavirotte N-acyl derivatives of amino acid mixtures derived from cereal protein hydrolysates and applications thereof
JPH06145024A (en) 1992-11-10 1994-05-24 Ajinomoto Co Inc Cosmetic
JPH08337519A (en) 1995-06-13 1996-12-24 Ajinomoto Co Inc Cosmetic
WO1998009611A1 (en) 1996-09-09 1998-03-12 Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic Cosmetic use of compounds with lipoaminoacid structure and cosmetic compositions with soothing activity incorporating some of these compounds
EP0839515A2 (en) 1996-10-29 1998-05-06 Kashima Oil Company Cosmetics comprising an n-acylamino acid ester
WO1999004757A1 (en) 1997-07-24 1999-02-04 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Use of a lipoaminoacid in a cosmetic formulation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2234399A1 (en) 1972-07-17 1974-01-31 Thomae Gmbh Dr K SKIN PROTECTION PRODUCTS
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
JPS61291700A (en) 1985-06-18 1986-12-22 ライオン株式会社 Foamable skin cleaning composition
WO1992021318A1 (en) 1991-06-03 1992-12-10 Givaudan-Lavirotte N-acyl derivatives of amino acid mixtures derived from cereal protein hydrolysates and applications thereof
JPH06145024A (en) 1992-11-10 1994-05-24 Ajinomoto Co Inc Cosmetic
JPH08337519A (en) 1995-06-13 1996-12-24 Ajinomoto Co Inc Cosmetic
WO1998009611A1 (en) 1996-09-09 1998-03-12 Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic Cosmetic use of compounds with lipoaminoacid structure and cosmetic compositions with soothing activity incorporating some of these compounds
EP0839515A2 (en) 1996-10-29 1998-05-06 Kashima Oil Company Cosmetics comprising an n-acylamino acid ester
WO1999004757A1 (en) 1997-07-24 1999-02-04 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Use of a lipoaminoacid in a cosmetic formulation

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076720A1 (en) * 2003-03-04 2008-03-27 Sancai Xie Personal care compositions having kinetin or zeatin
US20050019356A1 (en) * 2003-07-25 2005-01-27 The Procter & Gamble Company Regulation of mammalian keratinous tissue using N-acyl amino acid compositions
FR2873575A1 (en) * 2004-07-28 2006-02-03 Miyoshi Kasei Inc Coated powder for use in cosmetics, contains lipoamino acid composition containing N-acyl structure of amino acids e.g. proline, alanine, glycine, aspartic acid and glutamic acid and 12-18C fatty acid, which coats powder
EP1813252A1 (en) * 2006-01-30 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Cosmetic composition for matting the scalp
KR20110059844A (en) * 2008-09-03 2011-06-07 소시에떼 덱스플로와따시옹 더 쁘로뒤 뿌르 레 엥뒤스트리 쉬미끄, 에스. 에. 페. 페. 이. 세. Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, n-palmitoyl isoleucine, and n-cocoyl alanine as an active agent controlling the proportion of basal keratinocytes of the human skin epidermis and expressing the nuclear form of surviving, and anti-aging cosmetic composition comprising same
KR101652541B1 (en) 2008-09-03 2016-08-30 소시에떼 덱스플로와따시옹 더 쁘로뒤 뿌르 레 엥뒤스트리 쉬미끄, 에스. 에. 페. 페. 이. 세. Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, n-palmitoyl isoleucine, and n-cocoyl alanine as an active agent controlling the proportion of basal keratinocytes of the human skin epidermis and expressing the nuclear form of surviving, and anti-aging cosmetic composition comprising same
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives

Also Published As

Publication number Publication date
EP1013266A1 (en) 2000-06-28
US6274151B1 (en) 2001-08-14
FR2787323B1 (en) 2003-02-14
JP2000191426A (en) 2000-07-11
FR2787323A1 (en) 2000-06-23

Similar Documents

Publication Publication Date Title
US6440435B1 (en) Use of N-acylamino acid compounds as texturing agents
US6296859B1 (en) Synergistic composition comprising a compound of lipoamino acid structure and a water lily extract
JP5184758B2 (en) Novel reverse phase latex of copolymer of AMPS and N, N-dimethylacrylamide and its cosmetic use
ES2218992T3 (en) THICK POLYMER, PREPARATION PROCEDURE AND APPLICATIONS IN COSMETICS.
US20100215726A1 (en) Compositions for Diminishing the Appearance of Wrinkles
US9138602B2 (en) Powdery emulsifying composition of alkyl polyglycosides, use thereof for preparing cosmetic emulsions, and method for preparing same
US6346239B1 (en) Use in cosmetics of a reverse latex of nitrogenous salts of polyacrylate, novel latices, process for their preparation and cosmetic compositions incorporating them
JP2011051990A (en) Novel concentrated inverse latex, production method and use thereof in industry
US20010053801A1 (en) Inverse latexes based on white mineral oil, squalene or hydrogenated polyisobutene, cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions containing them
US20020032243A1 (en) Novel inverse latices self-invertible with respect to fatty acid esters, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising them
ES2535444T3 (en) New process for the preparation of reverse latex of acrylamide-based polymers and composition comprising said latex
US20110076245A1 (en) Novel inverse latices that are free of oxyethylene derivatives, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same
US7033600B1 (en) Inverse latex and use in cosmetics
US9144610B2 (en) Polymeric thickening agent free of acrylamide fragments, method for the preparation thereof, and composition containing same
US9101552B2 (en) Self-reversible reverse latex, and use thereof as a thickening agent in a cosmetic composition
JP6216782B2 (en) Novel surfactant-free self-reversing inverse latex and its use as a thickener in cosmetic compositions
US20110104084A1 (en) Novel compositions based on ethers of alkyl polyosides and on alkyl glyceryl ethers, use thereof as an emulsifier and cosmetic compositions containing same

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100827